Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
Germany
Charité Research Organisation GmbH, Berlin Universitätsklinikum Bonn AöR, Bonn Technische Universität Dresden, Dresden Universitätsklinikum Frankfurt, Frankfurt am Main Martin-Luther-Universität Halle-Wittenberg, Halle